Form 4: Vaxcyte Director Olivier Brandicourt Acquires Stock Options

Director Olivier Brandicourt acquired stock options in Vaxcyte, Inc. on May 1, 2025.

Summary

• On May 1, 2025, Olivier Brandicourt, a director of Vaxcyte, Inc., acquired 40,113 stock options.
• The exercise price of these options is $35.24.
• The options vest over 36 months, with 1/3 vesting on May 1, 2026, and the remainder vesting monthly thereafter, contingent upon continuous service to the company.
• The options expire on May 1, 2035.
• Following the transaction, Brandicourt directly owns 40,113 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns their interests with shareholders and incentivizes long-term value creation.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the director to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Vaxcyte, Stock Options, Form 4, Director, Brandicourt, PCVX, Acquisition